英国临床营养市场 - 2025-2033

2024 年英国临床营养市场规模达到 9.4093 亿美元，预计到 2033 年将达到 10.6955 亿美元，在 2025-2033 年预测期内的复合年增长率为 2.4%。

临床营养产品是帮助患者维持健康的药品。它透过提供足够的补充剂（如矿物质、维生素等）来帮助改善代谢系统。临床营养产品透过提供充足的补充剂（如矿物质、维生素和其他补充剂）有助于维持患者的健康并改善身体的代谢系统。

英国临床营养市场是一个致力于为有特殊健康需求的患者，特别是患有慢性疾病或营养不良的患者提供专门的营养支持和产品的行业。该市场包括多种产品，如肠内和肠外营养解决方案、医疗食品和膳食补充剂，旨在满足不同医疗保健环境中个人的营养需求。

临床营养学可以定义为研究饮食、营养和健康结果之间关係的领域。它涵盖与各种医疗状况相关的营养问题的预防、诊断和管理。临床营养的主要目标是确保患者获得足够的营养来支持他们的康復和整体健康，特别是在由于疾病或医疗而导致传统饮食摄取不足的情况下。这些因素推动了英国临床营养市场的扩张。

市场动态：

驱动因素与约束因素

代谢紊乱盛行率上升

英国临床营养市场由于代谢紊乱盛行率上升、医疗支出高以及新兴经济体中产阶级崛起等因素而经历成长，预示着市场正在不断增长。

肥胖、高血压、胰岛素抗性、高血脂等代谢性疾病发生率上升是全球重大公共卫生问题。这些疾病与慢性退化性疾病有关，例如第 2 型糖尿病、肥胖症和心血管疾病。营养在代谢紊乱中的作用已得到充分研究，但人们对阐明营养素/食物对人体代谢和代谢紊乱的作用的兴趣仍日益浓厚。

例如，根据国际糖尿病联盟的数据，总共使用了来自 39 个国家的 60 个资料来源来估计该地区成年人的糖尿病发生率。资料显示，2045年，欧洲地区的糖尿病盛行率（9.2%）和糖尿病患者数（6,100万人）将增加13%。

因此，代谢紊乱和其他慢性疾病数量的增加将直接增加对临床营养的需求，这将有助于市场在预测期内成长。此外，消费者对健康和保健的日益关注促进了英国临床营养市场的扩张。

缺乏临床营养意识

临床营养的需求日益增加，但已开发国家和发展中国家都缺乏对医疗保健和饮食的认识。由于缺乏对维生素和营养的正确知识以及不正确的讯息，这种缺乏认识会导致缺陷和疾病。对健康和卫生的教育和直接支持是不够的。儘管有活动提高人们对不同疾病的临床营养益处的认识，但人们仍然缺乏对各种疾病的临床营养的了解，这预计会阻碍市场的发展。

然而，缺乏认识（尤其是在新兴国家）和严格的政府监管是导致替代营养方式采用率较低的一些限制因素。临床营养市场的成长可能会受到影响在世界上最不发达地区，由于拒绝合理的营养摄取方式和缺乏对新方法的接受，这些地区的生活水平相对较低。

公众普遍缺乏对临床营养在管理健康状况方面的重要性的认识。许多人没有认识到营养如何影响慢性疾病或有助于疾病的恢復。因此，上述因素可能会限制英国临床营养市场的潜在成长。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动态

• 影响因素
  • 驱动程式
    • 代谢紊乱盛行率上升
  • 限制
    • 缺乏临床营养意识
  • 机会
  • 影响分析

第五章：战略洞察与产业展望

• 市场领导者和先驱者
  • 新兴先锋和杰出参与者
  • 拥有最大、最畅销品牌的成熟领导者
  • 拥有成熟产品的市场领导者
• CXO 观点
• 最新进展与突破
• 案例研究/正在进行的研究
• 监管和报销情况
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲
• 波特五力分析
• 供应链分析
• 专利分析
• SWOT 分析
• 未满足的需求和差距
• 市场进入和扩张的推荐策略
• 情境分析：最佳情况、基本情况和最坏情况预测
• 定价分析和价格动态
• 关键意见领袖

第 6 章：依产品类型

• 婴儿营养
• 肠内营养
• 肠外营养

第七章：依年龄组

• 成人
• 儿科

第 8 章：按给药途径

• 口服
• 肠内
• 肠外

第九章：按应用

• 肿瘤学
• 代谢紊乱
• 胃肠道疾病
• 神经系统疾病
• 其他的

第 10 章：按配销通路

• 医院药房
• 零售药局
• 网路药局

第 11 章：竞争格局

• 竞争格局
• 市场定位/份额分析
• 併购分析

第 12 章：公司简介

• Abbott Laboratories (Abbott Nutrition)
• 公司概况
• 产品组合
  • 产品描述
  • 产品关键绩效指标 (KPI)
  • 历史和预测产品销售量
  • 产品销售量
• 财务概览
  • 公司收入
  • 地区收入份额
  • 收入预测
• 关键进展
  • 合併与收购
  • 关键产品开发活动
  • 监管部门批准等
• SWOT 分析
• Nestle Health Science
• Baxter International Inc
• B. Braun Melsungen AG
• Danone (Nutricia)
• BASF SE
• Perrigo Company PLC
• DSM-Firmenich AG
• AYMES International Ltd
• Nualtra

第 13 章：附录

The U.K. clinical nutrition market reached US$ 940.93 million in 2024 and is expected to reach US$ 1,069.55 million by 2033, growing at a CAGR of 2.4 % during the forecast period 2025-2033.

Clinical nutrition products are pharmaceutical products that help keep a patient healthy. It helps to improve the metabolic system by providing adequate supplements such as minerals, vitamins, and others. Clinical nutrition products are useful in maintaining the patient's health and improving the body's metabolic system by providing adequate supplements, such as minerals, vitamins, and other supplements.

The clinical nutrition market in the UK is a sector dedicated to providing specialized nutritional support and products for patients with specific health needs, particularly those suffering from chronic diseases or malnutrition. This market includes a diverse range of products such as enteral and parenteral nutrition solutions, medical foods, and dietary supplements that are designed to meet the nutritional requirements of individuals in various healthcare settings.

Clinical nutrition can be defined as the field that examines the relationship between diet, nutrition, and health outcomes. It encompasses the prevention, diagnosis, and management of nutritional issues associated with various medical conditions. The primary goal of clinical nutrition is to ensure that patients receive adequate nutrients to support their recovery and overall health, especially in situations where traditional dietary intake is insufficient due to illness or medical treatment. These factors have driven the U.K. clinical nutrition market expansion.

Market Dynamics: Drivers & Restraints

Rise in the Prevalence of Metabolic Disorders

The UK clinical nutrition market is experiencing growth due to factors such as rising metabolic disorders prevalence, high healthcare spending, and the rise of the middle class in emerging economies, indicating a growing market.

The rise in the prevalence of metabolic diseases, such as obesity, hypertension, insulin resistance, and hyperlipidemia, is a significant public health issue worldwide. These disorders are associated with chronic degenerative diseases, such as type 2 diabetes, obesity, and cardiovascular disease. The role of nutrition in metabolic disorders is well investigated, but there is still a growing interest in elucidating the nutrients/foods that execute their actions on human metabolism and metabolic disorders.

For instance, according to the International Diabetes Federation, a total of 60 data sources from 39 countries were used to generate diabetes estimates among adults in the region. According to the data, the diabetes prevalence (9.2%) and number of people with diabetes (61 million) in Europe region will increase 13 % by 2045. Europe region has the highest number of children and adolescents with type 1 diabetes (295,000) as well as the highest incidence annually with 31,000 new cases per year.

Hence, the rise in the number of metabolic disorders and other chronic diseases will increase the demand for clinical nutrition directly which will help the market to grow during the forecast period. Moreover, the increasing focus of consumers on health and wellness contributes to the U.K. clinical nutrition market expansion.

Lack of Awareness for Clinical Nutrition

The demand for clinical nutrition is increasing, but there is a lack of awareness about healthcare and diet in both developed and developing countries. This lack of understanding leads to deficiencies and disorders due to a lack of proper knowledge of vitamins and nutrition, and incorrect information. Education and direct support for health and hygiene are not sufficient. Despite campaigns promoting awareness about clinical nutrition benefits for different diseases, there is still a lack of understanding about clinical nutrition for various illnesses, which is expected to hamper the market.

However, lack of awareness especially in emerging countries, and stringent government regulations are a few of the restraints that may result in lower adoption of alternate means of nutrition. The clinical nutrition market growth can be affected in the least developed regions of the world with comparatively lower standards of living attributed to the refusal of rationalized means to consume nutrition and, lack of acceptance of newer approaches.

There is a widespread lack of understanding among the general public regarding the significance of clinical nutrition in managing health conditions. Many people fail to recognize how nutrition can influence chronic diseases or aid in recovery from illnesses. Thus, the above factors could be limiting the U.K. clinical nutrition market's potential growth.

Segment Analysis

The U.K. clinical nutrition market is segmented based on Product Type, Age Group, route of administration, application, Distribution Channel, and region.

Product Type:

The enteral nutrition segment is expected to dominate the U.K. clinical nutrition market share

The enteral nutrition segment holds a major portion of the U.K. clinical nutrition market share and is expected to continue to hold a significant portion of the U.K. clinical nutrition market share during the forecast period. Enteral nutrition is an essential aspect of healthcare for individuals with a functioning digestive system who are unable to eat or drink. Nestle Health Science, a leader in the field, offers a wide range of enteral feeding products and solutions designed to support various life stages, from pediatrics to healthy aging.

If the gut is working normally to absorb food and nutrients, then Enteral Nutrition is the preferred way of delivering nutritional support. In some patients, enteral nutrition may have to be delivered into the gut through a tube, but in others, it may be possible for them to take this by mouth. This segment has seen substantial growth due to several factors, such as the rising elderly population, the growing incidence of chronic diseases, and a trend towards care being provided in home settings.

Furthermore, major players in the industry key initiatives and expansion of the industry that would propel this segment growth in the U.K. clinical nutrition market. For instance, in October 2022, Galen Medical Nutrition, a subsidiary of Galen Limited, launched TYR EASY Tablets in the UK, marking the first solid-dose protein substitute option for individuals over 8 years old with tyrosinemia. This provides patients with a greater variety of protein substitutes to better suit their individual needs.

Also, in May 2021, Willows Veterinary Centre expanded its clinical nutrition service by launching a specialist-led parenteral nutrition service. Willows is one of the few specialist centers in Europe with a board-certified specialist in clinical nutrition. This service provides intravenous nutrition, including protein, carbohydrates, and fat solutions, to patients when other feeding methods are not possible. These factors have solidified the segment's position in the U.K. clinical nutrition market.

Competitive Landscape

The major global players in the pollinosis market include Abbott Laboratories (Abbott Nutrition), Nestle Health Science, Baxter International Inc, B. Braun Melsungen AG, Danone (Nutricia), BASF SE, Perrigo Company PLC, DSM-Firmenich AG, AYMES International Ltd, and Nualtra among others.

Key developments

• In January 2023, Nutricia, a Danone-owned company, launched its first plant-based medical nutrition drink, Fortimel PlantBased Energy, to address the nutritional needs of individuals who are malnourished or at risk of malnutrition due to illness. This ready-to-drink oral nutritional supplement is made with high-quality plant protein from pea and soy sources, making it suitable for vegans, vegetarians, flexitarians, and those with cow's milk protein allergies. It is designed to match the nutritional profile of the original dairy formula.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The U.K. clinical nutrition market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Age Group
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Application
• 3.5. Snippet by Distribution Channel
• 3.6. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rise in the Prevalence of Metabolic Disorders
  • 4.1.2. Restraints
    • 4.1.2.1. Lack of Awareness for Clinical Nutrition
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

• 5.1. Market Leaders and Pioneers
  • 5.1.1. Emerging Pioneers and Prominent Players
  • 5.1.2. Established leaders with largest largest-selling Brand
  • 5.1.3. Market leaders with established Product
• 5.2. CXO Perspectives
• 5.3. Latest Developments and Breakthroughs
• 5.4. Case Studies/Ongoing Research
• 5.5. Regulatory and Reimbursement Landscape
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa
• 5.6. Porter's Five Force Analysis
• 5.7. Supply Chain Analysis
• 5.8. Patent Analysis
• 5.9. SWOT Analysis
• 5.10. Unmet Needs and Gaps
• 5.11. Recommended Strategies for Market Entry and Expansion
• 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 5.13. Pricing Analysis and Price Dynamics
• 5.14. Key Opinion Leaders

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Infant Nutrition*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Enteral Nutrition
• 6.4. Parenteral Nutrition

7. By Age Group

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 7.1.2. Market Attractiveness Index, By Age Group
• 7.2. Adult*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Pediatric

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Oral*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Enteral
• 8.4. Parenteral

9. By Application

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.1.2. Market Attractiveness Index, By Application
• 9.2. Oncology*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Metabolic Disorders
• 9.4. Gastrointestinal Disorders
• 9.5. Neurological Disorders
• 9.6. Others

10. By Distribution Channel

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.1.2. Market Attractiveness Index, By Distribution Channel
• 10.2. Hospital Pharmacies*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Retail Pharmacies
• 10.4. Online Pharmacies

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Abbott Laboratories (Abbott Nutrition) *
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio
    • 12.1.2.1. Product Description
    • 12.1.2.2. Product Key Performance Indicators (KPIs)
    • 12.1.2.3. Historic and Forecasted Product Sales
    • 12.1.2.4. Product Sales Volume
  • 12.1.3. Financial Overview
    • 12.1.3.1. Company Revenue's
    • 12.1.3.2. Geographical Revenue Shares
    • 12.1.3.3. Revenue Forecasts
  • 12.1.4. Key Developments
    • 12.1.4.1. Mergers & Acquisitions
    • 12.1.4.2. Key Product Development Activities
    • 12.1.4.3. Regulatory Approvals etc.
  • 12.1.5. SWOT Analysis
• 12.2. Nestle Health Science
• 12.3. Baxter International Inc
• 12.4. B. Braun Melsungen AG
• 12.5. Danone (Nutricia)
• 12.6. BASF SE
• 12.7. Perrigo Company PLC
• 12.8. DSM-Firmenich AG
• 12.9. AYMES International Ltd
• 12.10. Nualtra

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us